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Abstract
Microbial metabolites are an emerging class of mediators influencing CD4+ T cell function. To 
advance the understanding of direct causal microbial factors contributing to Crohn’s disease, we 
screened 139 predicted Crohn’s disease-associated microbial metabolites for their bioactivity on 
human CD4+ T cell functions induced by disease-associated T helper 17 (Th17) polarizing 
conditions. We observed 15 metabolites with CD4+ T cell bioactivity, 3 previously reported and 
12 unprecedented. A deeper investigation of the microbe-derived metabolite, ascorbate, revealed 
its selective inhibition on activated human CD4+ effector T cells, including IL-17A-, IL-4-, and 
IFNγ-producing cells. Mechanistic assessment suggested the apoptosis of activated human CD4+ 
T cells associated with selective inhibition of energy metabolism. These findings suggest a 
substantial rate of relevant T cell bioactivity among Crohn’s disease-associated microbial 
metabolites, and evidence for novel modes of bioactivity, including targeting of T cell energy 
metabolism.
Keywords
Crohn’s disease; Microbial metabolites; Th17; Ascorbate; Immunometabolism
Introduction
Abnormalities of intestinal microbial composition are strongly associated with inflammatory 
bowel diseases1–3. In the healthy state, much evidence suggests that small molecule products 
of the microbiota (microbial metabolites) are important modulators of normal host 
physiology4–6. Among these, the literature includes only a handful of bioactive microbial 
metabolites, and few metabolites directly affect cellular targets of Crohn’s disease 
relevance7, 8. In Crohn’s disease, previous multi-omic studies suggest an association with 
alteration of microbial energy metabolism, enrichment of carbohydrate, lipid, cofactor and 
vitamin metabolism, and depletion of amino acid biosynthesis9–11. Certain of these 
microbial metabolites are known to influence important aspects of host metabolism12, 
activity of intestinal epithelial stem cells7, and regulation of diverse immune cellular 
responses8, 13, 14. For example, short chain fatty acids (SCFAs) such as butyrate are known 
for their mechanisms of action on immune responses through the inhibition of histone 
deacetylase14. Tryptophan catabolites induce T cell cytokine expression through a process 
involving ligand-activated aryl hydrocarbon receptor, AHR15. However, most inferred 
microbial metabolites remain untested for bioactivity on disease-relevant host responses, and 
unresolved for their mechanisms of action.
In genetically susceptible individuals, Crohn’s disease results from inappropriate immune 
responses to the unique intestinal microbiota16, 17. Functional assessment of Crohn’s disease 
genetic loci revealed the involvement of CD4+ effector T helper signaling and the Th17-
IL23 pathway18, 19. Both clinical studies and pre-clinical colitis studies strongly link Th17 
cell responses and the IL-17 pathway to the pathogenesis of Crohn’s disease20–24. Given 
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their pathogenic role, Th17 cells became a therapeutic target25, but clinical trials revealed 
unexpected inefficacy and disease exacerbation26–30. Subsequent work has uncovered 
dichotomous roles of the IL-17 pathway in Crohn’s disease progression, reflecting the 
differential roles of Th17 cells in disease induction and resolution31. This affirms the 
importance of Th17 in Crohn’s disease, but suggests complexity in how the intestinal 
microbiome and its products may be modifiers of mucosal effector T cell function.
To determine how Crohn’s disease-associated microbiome and its products modulate CD4+ 
T cell responses, we applied a set of bioinformatics packages to tabulate a list of microbial 
metabolites predicted to be differentially abundant in Crohn’s disease. We functionally 
screened these metabolites by adding them to CD4+T cell cultures together with Th17-
polarizing cytokines. This conceptually recapitulates the in vivo setting, in which 
lymphocytes simultaneously encounter bacterial products and inflammatory cytokines in the 
sub-mucosa or draining lymph nodes. Our screen revealed a substantial frequency (11%) of 
metabolites that modulated T cell activity, with different patterns of inhibition and 
augmentation. Detailed study of one microbe-derived metabolite, ascorbate, demonstrated 
potent inhibition of activated effector CD4+ T cells associated with the disruption of energy 
metabolism. These findings support the idea that disease-associated microbial metabolites 
may have a significant role in the pathogenesis of Crohn’s disease.
Results
Strategy to identify microbial metabolites modulating T cell responses
To predict Crohn’s disease-associated microbial metabolites, we performed a set of 
bioinformatics approach on the fecal microbiome dataset in PRISM cohort32 (see 
supplementary information). This approach predicted the microbial metabolites which are 
differentially produced based on Crohn’s disease and healthy microbiome, and we selected 
the subset of 139 commercially available metabolites to test their functions on modulating 
CD4+ T cell responses. Supplementary Table 1 shown the list of tested metabolites. Figure 
1a shown the summarized workflow of screen strategy. Briefly, purified human blood CD4+ 
T cells were cultured with different concentrations of each metabolite in the presence of 
standard 14 days of Th17 polarization culture conditions (anti-CD3, anti-CD28, IL-6, IL-1β, 
and IL-23)33. We assessed Th17 polarization by levels of secreted cytokines, and validated 
by the percentage of Th17 cells by flow cytometry (Supplementary Figure 2).
Differential metabolite effects on T cell cytokine profiles
The primary screening revealed eighteen bioactive metabolites based on a relaxed cut-off in 
multivariate analysis of variance (Figure 1b). We performed a confirmatory screening in 
independent healthy individuals to validate the primary screen and refine dose-dependent 
responses (two-way ANOVA). Figure 1c summarizes results for all screened metabolites 
with respect to toxicity and secreted cytokine production. The toxicity was defined by the 
endpoints of cell death and reduced cell numbers. We tabulated metabolite conditions that 
significantly increased toxicity, and excluded them from downstream cytokine analyses. 
Notably, we did not observe any metabolites that significantly enhanced cell numbers 
(Supplementary Figure 3).
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Sixteen metabolites (11%) were toxic based on cell death at all tested conditions in both 
donors. A total of fifteen metabolites (11%) displayed reproducible effects on T cell 
cytokine production, and were classified as validated bioactive. Three metabolites (2%) 
showed inconsistent cytokine changes between two individual experiments, and were 
classified as putatively bioactive.
The fifteen validated bioactive metabolites varied in their pattern of effects on cytokine 
production (Table 1). Three of these metabolites were previously reported for analogous 
effects on T cells13, 34, 35 (Supplementary Figure 4). Strikingly, the action of the other 
twelve metabolites are unprecedented, to our knowledge, for an effect on T cell cytokine 
production. Figure 1d summarizes the relative cytokine secretion for the twelve novel 
bioactive metabolites. Unsupervised hierarchical clustering classified the metabolites into 
patterns of inhibitory and augmented responses. Among them, six metabolites are fatty acid 
intermediates or end products based on the Human Metabolome Database (HMDB)36.
Representative bioactive metabolites altering CD4+ T cell cytokine secretion
We observed distinct patterns of altered cytokine production and we organized the data 
between main and supplementary figures based on the criteria of the dose-dependency. The 
first group of metabolites induced global changes in cytokine production. GDP-mannose 
decreased the production of eight cytokines (pan-inhibition) at the dose range of 0.1 to 1 
mM (Figure 2a). Three other metabolites (HMG-CoA, CoA, and mevalonate) similarly 
decreased the production of all tested cytokines at high concentration (Supplementary Figure 
5a). Instead of pan-inhibition, L-homocysteine (1 mM) augmented production of most tested 
cytokines (Supplementary Figure 5b).
Other metabolites showed selective effects on Th17 cytokines. Ascorbate decreased Th17-
related cytokine production (Figure 2b), whereas there was no statistically significant change 
for other cytokines in this Th17-polarizing condition. Three metabolites at indicated 
conditions (0.1 mM glutaryl-CoA, 1mM hexanoyl-CoA, and 1 mM isopentenyl diphosphate) 
enhanced the production of IL-17A and IL-17F (Supplementary Figure 6a).
The third group of metabolites selectively altered production of certain non-Th17 cytokines. 
Oleic acid and linoleic acid increased IFNγ in a dose-dependent fashion (Figure 2c and 2d); 
In contrast, pyridoxine phosphate decreased the production of TNFα, IFNγ, and IL-10 at 0.1 
mM (Supplementary Figure 6b).
Ascorbate inhibits T cell cytokines in both polarized and non-polarized conditions
Among all twelve metabolites, ascorbate is the only microbe-derived metabolite that human 
cannot synthesize, which drew our attention to this metabolite for deeper validation and 
mechanistic assessment. To further validate ascorbate bioactivity under Th17 polarizing 
conditions, we performed four additional biological replicates, and found that ascorbate 
consistently inhibited the production of Th17 cytokines. Flow cytometry analysis 
demonstrated that ascorbate induced a dose-dependent reduction in IL-17A-producing CD4+ 
T cells, including both IL-17A single positive T cells and IFNγ/IL-17A double positive cells 
(Figure 3a). Measurement of cytokine secretion by Luminex confirmed the ascorbate 
inhibitory effect. All the cardinal Th17 cytokines (IL-17A, IL-17F and IL-22) were reduced 
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by more than 50% after 100 uM ascorbate treatment (Figure 3b). These data confirm that 
ascorbate inhibits the production of Th17 and Th17-related cytokines under Th17-polarizing 
conditions.
To investigate whether this inhibiting effect was specific to the Th17 subset, we cocultured 
CD4+ T cells with ascorbate under non-selective activating conditions (anti-CD3/CD28 
without Th17-polaring cytokines (Figure 3c). In the presence of ascorbate, IFNγ, IL-4, and 
IL-17A- producing CD4+ T cells were all reduced, whereas IL-10 producing cells were 
preserved. Both IL-17A-single positive cells and IFNγ/IL-17A-double positive cells were 
reduced in the presence of ascorbate. We concluded that ascorbate not only inhibited Th17 
cells, but also reduced the activation of most other subsets of effector T cells (excluding 
IL-10-producing T cells).
Ascorbate selectively inhibits activated but not resting CD4+ T cells
We next determined whether ascorbate regulated all CD4+ T cells, including resting T cells 
and activated T cells. We cultured CD4+ T cells in resting and activating conditions for 48 
hours in the absence or presence of 100 uM ascorbate. Ascorbate selectively inhibited the 
upregulation of the activation marker CD154 in activating conditions (Figure 4a and 4b). 
AnnexinV and 7-AAD staining further demonstrated that activated but not resting T cells 
underwent programmed cell death after 48 hours of ascorbate treatment (Figure 4c). These 
data illustrated that ascorbate selectively inhibited activated versus resting T cells.
Ascorbate selectively inhibits glycolytic-dependent activated T cells through GLUT1
Among the several metabolic roles of ascorbate is its inhibition of glycolytic energy 
metabolism concomitant cell death in glycolytic-dependent cells37. Consistent with these 
findings, we observed an increase of oxygen consumption rate (OCR) and the significant 
increase of extracellular acidification rate (ECAR) in the activated T cells (Figure 5a and 
5b). The decreased ratio of OCR/ECAR between the resting and activated condition further 
validated the switch of glycolysis in the activated condition. In addition, in the ascorbate-
treated condition, we observed a significant reduction of ECAR in the activated but not 
resting T cells, suggesting that ascorbate treatment may affect the overall increase of OCR/
ECAR ratio via reduction in glycolysis (Figure 5b).
It is well known that TCR activation, specifically CD28 signaling, directly controls the 
metabolic switch to glycolysis by up-regulating the expression of glucose transporter 1 
(GLUT1), and remodeling activity of downstream biochemical pathways to favor glycolytic 
versus oxidative phosphorylation energy production in T cells 38–40. Since GLUT1 is also a 
transporter for the oxidized form of ascorbate38, we hypothesized that ascorbate selectively 
inhibits glycolytic-dependent activated T cells through GLUT1. To evaluate the role of 
GLUT1 in ascorbate-induced inhibition, the GLUT1 and scramble siRNA were transfected 
into activated CD4+ T cells and the knockdown efficiency was validated by GLUT1 western 
blot (Supplementary Figure 7). Like cells treated with ascorbate alone, we observed a 
significant decrease of ECAR (Figure 5d, scramble) and significant increase of OCR/ECAR 
ratio in the ascorbate-treated scramble siRNA condition (Figure 5e, scramble). In contrast, 
these changes were extinguished in the ascorbate-treated GLUT1 siRNA condition. This 
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finding suggests that GLUT1 is required for the ascorbate-induced alteration of energy 
metabolism in activated T cells (Figure 5d and 5e). Together, these data support that a 
selective inhibitory effect of ascorbate on activated T cells was related to a mechanism 
which regulated energy metabolism through a GLUT1-dependent action.
Ascorbate production by microbial taxa associated with Crohn’s disease
To investigate whether gut microbes can produce ascorbate, we performed a reverse 
metagenomic search for the bacterial genomes that contained ascorbate biosynthesis 
enzymes. The metabolic pathways utilized by microbes to produce ascorbate de novo are 
largely unknown, but biotechnology has suggested two microbial pathways to manufacture 
L-ascorbate from D-glucose41. We therefore investigated the chemical reactions in these 
processes, and tabulated the metabolic enzymes and corresponding metagenes involved in 
ascorbate synthesis reactions. Using this tabulation, we performed a reverse metagenomics 
search of human fecal microbiota bearing some or all of the genes in the archetypal D-
sorbitol and 2,5-diketo-D-gluconic acid pathways of ascorbate biosynthesis (Supplementary 
Tables 2 and 3). We identified 5 Operational Taxonomic Units (OTUs) bearing the 
ascertainable metagenes of the D-sorbitol pathway, all of them in the Crohn’s disease-
associated genus Burkholderia (Figure 6a). We also identified 120 OTUs for the 2,5-diketo-
D-gluconic acid ascorbate pathway; of these, the most prevalent taxa belonged to the 
Crohn’s disease-associated genera Pseudomonas and Erwinia (Figure 6b). To directly assess 
ascorbate production by these microbes, we assembled a collection of three clinical isolates 
of Burkholderia and two strains of Pseudomonas aeruginosa. After aerobic culture to 
stationary phase, ascorbate production was detectable in both Pseudomonas strains (Figure 
6c), but not in the Burkholderia isolates (data not shown). These findings indicate that 
certain Crohn’s disease-associated microbiota are proficient at ascorbate biosynthesis, and 
point to the 2,5-diketo-gluconic acid pathway as a potential mechanism for this production.
Discussion
By screening microbial metabolites using primary human CD4+ T cells in Th17 polarizing 
culture conditions, we identified three known and twelve novel microbial metabolites with 
the potential to module T cell cytokine production. A detailed study of one novel microbial-
derived metabolite, ascorbate, revealed inhibition of Th17 and activated T cell formation by 
a mechanism involving blockade of glycolytic energy metabolism. We metagenomically 
inferred and functionally validated examples of Crohn’s disease-associated microbiota 
proficient for ascorbate production. These findings suggest a substantial frequency of 
relevant T cell bioactivity among Crohn’s disease-associated microbial metabolites, and 
evidence for novel modes of bioactivity, including targeting of T cell energy metabolism.
This study emphasizes the importance of environmental metabolic cues to modulate CD4+ T 
cell functions, notably via differentiation and activation of specific subsets of CD4+ T cells 
with distinct cytokine expression patterns42, 43. Three bioactive metabolites identified in our 
study confirmed previous observations of these metabolites as selective mediators of such 
differentiation and activation13, 34, 35. The bioactivity of twelve additional metabolites for 
human CD4+ T cells did not have literature precedents to our knowledge. The diversity of 
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their effects on T cell cytokine function suggests that their mechanistic assessment may 
reveal new insights on the action of microbial metabolites in CD4+ T cell function, and the 
role of these actions in disease biology.
We studied the mechanism of ascorbate, since it was unknown for inhibitory action on 
activated CD4+ T cells until a recent independent study44. Among its several biochemical 
roles, ascorbic acid in its oxidized form (dehydroascorbate), transported by the GLUT 
hexose transporter family, inhibits glycolytic energy metabolism by oxidative inactivation of 
glyceraldehyde 3-phosphate dehydrogenase, an apex enzyme in glycolytic energy 
metabolism37. The present study demonstrated that in active CD4+ T cells, the predominant 
action of ascorbate was as an inhibitor of glycolytic energy production. Concordantly, we 
also observed that this effect was dependent on GLUT1, the major T cell hexose transporter 
isoform38, 45, and the transporter class responsible for uptake of oxidized ascorbate46, 47.
Intracellular dehydryoascorbate is an efficient substrate for enzymatic glutathione oxidation 
48
, and at high levels it rapidly increases GSSH levels leading to downstream endogenous 
reactive oxygen species (ROS)49. GAPDH is a sensitive target for oxidative inhibition via 
two pathways. First, ROS induces S-glutathionylation or S-sulfonylation of the cysteine 
residue on GAPDH, diminishing GAPDH activity 50–52. In addition, accumulation of 
endogenous ROS induces DNA damage leading to activation of PARP, depleting levels of 
NAD+, the substrate for GAPDH 37, 53. Both mechanisms cause the reduction of GAPDH 
activity, which leads to the impaired glycolysis, and cell death in selectively glycolysis-
dependent cells.
It is well known that the early phase of T cell activation induces a metabolic switch to and 
dependence upon aerobic glycolysis38–40. This provides a plausible mechanism by which 
ascorbate, via interruption of glycolytic energy production, may account for the selective 
functional inhibition and apoptosis of activated CD4+ T cells. However, a recent report 
observed that after completion of Th17 induction, these cells shift again to oxidative 
phosphorylation as their preferential energy source54. Incorporating this point, we speculate 
that the potential in vivo action of ascorbate on Th17 cells may be limited to the stages of 
Th17 induction and activation and to their relevant anatomic sites (such as mesenteric nodes 
in the case of intestinal Th17 cells).
A distinct action of ascorbate on energy metabolism is its augmentation of oxidative 
phosphorylation via alpha-ketoglutarate-dependent mitochondrial ascorbic acid recycling. 
This is mediated by reduced ascorbate, which is transported at the surface or mitochondrial 
membrane by the sodium transporter family members SVCT1 and 255–58. However, in our 
study the ascorbate effect on OCR was modest and not altered by GLUT1 knockdown 
(Figure 5), suggesting that augmented TCA cycling was a minor mode of action for 
ascorbate on T cell energy metabolism. A recent study reported SVCT2 expression and 
sodium-dependent ascorbate uptake in T cells, and ascorbate-mediated inhibition of T cell 
activation44. This study was distinguished from the present one by the requirement for 
supraphysiologic levels of ascorbate (0.5 mM), and the role of energy metabolism was not 
delineated. It is possible that the inhibitory mechanism of high ascorbate is distinct, and 
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suggests a role for mitochondrial SVCT2, since it is a low affinity ascorbate receptor at high 
divalent cation levels characteristic of the cytoplasm.57
We also observed that ascorbate inhibits the production of IFNγ-, IL-4, and IL-17A, but not 
IL-10. Unlike other CD4+ T cell subsets, induced Tregs (which inhibit effector T cell 
responses in part through IL-10 release) do not substantially shift to glycolytic energy 
metabolism39, 40, and this may account for their resistance to ascorbate inhibition. Moreover, 
in mice ascorbate facilitates the demethylation of Foxp3 enhancer and promotes Treg cell 
function59, 60. Taken together, these observations suggest that ascorbate as an environmental 
cue that may selectively inhibit effector CD4+ T cell responses.
An issue raised by these observations is the physiological role of dietary ascorbate versus 
local microbial ascorbate production. Unlike most eutherians, humans and primates require 
ascorbate intake, because they genetically lack the enzyme responsible for the last step in 
ascorbate synthesis, L-gulonolactone oxidase61. Previous work indicates that microbial 
ascorbate is not the major nutritional source for vitamin C in humans62, suggesting the 
importance of dietary intake of ascorbate in human. However, dietary ascorbate is largely 
absorbed before transit to the colon, so local microbial production may be a significant 
contributor to luminal ascorbate in the distal intestine. The predicted ascorbate-producing 
genera are Proteobacteria, an uncommon intestinal phylum most prevalent in the colon. 
Pseudomonas aeruginosa and related species are notable for their production of redox-active 
small molecules that modify the cellular redox state, acting as inter-microbial signals to 
control biofilm formation63. Ascorbate may represent an additional class of redox-active 
molecules involved in such inter-microbial interaction. Microbial genetics and ecologic 
studies are necessary to assess the control and bioavailability of ascorbate in the gut, and test 
its potential role in microbial ecology.
Clinically, ascorbate levels and the ratio of oxidized versus reduced form of ascorbate are 
distinct in IBD patients versus healthy subjects 64. Genetic variations in the sodium-
dependent ascorbate transporter gene, SLC23A1, have been significantly associated with 
susceptibility to Crohn’s disease65. The disease variant of human SLC23A1 results in lower 
transporter activity and decreased intracellular ascorbate. Decreased ascorbate transport 
limits the capacity to prevent oxidative tissue damage and impair recovery from mucosal 
injury 66. However, the mechanistic basis of these disease-associated phenotypes has not yet 
been probed in experimental animal models, because except for primates, eutherians are 
proficient for ascorbate synthesis. Such studies, and testing the potential in vivo roles of 
microbial ascorbate on CD4+ T cells and Crohn’s disease, await genetic engineering of mice 
bearing the human-homologous L-gulonolactone oxidase deficiency.
Collectively, this study demonstrates the utility of a screening strategy to probe the T cell 
bioactivity of Crohn’s disease -associated microbial metabolites. These results suggest that 
the balance of luminal metabolites could be important to maintain physiological CD4+ T 
cell functions of the intestinal mucosa. The implications for future studies include testing in 
vivo whether levels of bioactive metabolites correlate with disease state, the abundance of 
cognate producing microbial taxa, and cognate changes in local T cell function attributable 
to these metabolites.
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Methods
Human blood sample collection and T cell isolation
We recruited healthy donors at UCLA immune assessment core, and collected blood 
samples according to an IRB protocol approved by the institutional review committee of 
University of California, Los Angeles (Protocol # 10-001689). Human CD4+ T cells were 
isolated using Rosettesep Human CD4+ T cell enrichment cocktails (StemCell™ 
technology) following manufacturer’s instructions. Purified CD4+ T cells were confirmed to 
be > 95% pure by flow cytometry and the T cell subset composition was monitored 
(Supplementary Figure 1). We cultured T cells with soluble anti-CD28 (0.2 ug/ml) 
antibodies on 96-well plates pre-coated with anti-CD3 antibodies (1ug/ml). Interleukin 2 
(IL-2) was added at 4.8 U/ml (2 ng/ml). We induced Th17 differentiation with 50 ng/ml 
IL-6, 50 ng/ml IL-1β and 50 ng/ml IL-23 33. We refed T cells at day 7 with medium 
containing the same Th17 polarizing cytokines and further cultured for another 7 days. We 
collected supernatants for multiplex Luminex cytokine analysis, and analyzed T cells by 
intracellular flow cytometry.
Cell survival assay
The survival of metabolites-conditioned cells was examined by SYTOX™ Red dead cell 
stain (Molecular Probes, Cat.S34859), which is a nucleic acid stain that penetrates cells with 
compromised plasma membranes. We used the SYTOX™ Red dead cell stain after cell 
surface marker staining, and detected SYTOX Red levels by flow cytometry.
Intracellular Flow Cytometry
At the end of the 14-day culture, T cells were stimulated with Leukocyte activation cocktail 
with BD GolgiPlug (BD Biosciences, Cat. 550583) for 4 hours and washed in FACS buffer. 
BV650-conjugated CD3 (Clone OKT3) and PE-CF594-conjugated CD4 (Clone OKT4) 
antibody were used to detect these cell surface markers. We performed intracellular fixation 
and permeabilization with a commercial buffer set (eBiosciences, Cat. 88-8824). The 
following antibodies were used to detect intracellular cytokines: APC-conjugated IL-17A 
(Clone eBio64DEC17), FITC-conjugated IFNγ (Clone 4S.B3), PE-conjugated IL-10 (Clone 
JES3-9D7), and PE-Cy7-conjugated IL-4 (Clone 8D4-8) were purchased from eBioscience 
or Biolegend).
Cell respiration measurements
We activated isolated CD4+ T cells on plates coated with 10 ug/ml anti-CD3 and 10ug/ml 
anti-CD28, and stimulated in the presence of 10 ng/ml IL-2 as the activated condition, and 
10 ng/ml IL-7 as the resting condition. After 48 hours, activated or resting cells were 
collected, washed with unbuffered DMEM (2 g/L glucose), and seeded into CELL-TAK™ 
(Corning Cat. 354240)-covered 96-well plates (Agilent Seahorse XF96) (0.5 million cells/
well) for OCR and ECAR measurement. We measured cellular OCRs and ECARs as 
described previously38. Oxygen consumption was blocked by oligomycin (1.5 uM), an ATP 
synthase inhibitor; the ionophore FCCP (carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone; 2uM and 3 uM) assayed maximal respiratory capacity of 
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mitochondria, whereas rotenone plus antimycin A (3 uM), a mitochondrial inhibitor, was 
used to block mitochondrial respiration. Three independent experiments were performed, 
and 3 technical replicates per experiment were measured to calculate the mean ± SEM for 
each time point.
Bioinformatic prediction of Crohn’s disease-associated microbial metabolites
Using a previously reported PRISM dataset32 of microbial composition at the level of OTUs 
from 16S rRNA gene amplicon sequencing data, we tabulated microbial count data for 
healthy and Crohn’s disease subjects at the subject level, and converted them to imputed 
metagene data using PICRUSt67. We then determined the relative abundance of enzymatic 
pathways using HUMAnN268, with pathway end-products identified using UniRef and 
MetaCyc databases. Making the assumption that metabolite abundance is the sum of 
abundances of the generating enzymes, we calculated the predicted abundance of each 
metabolite using the average of most abundant route through each pathway.
Disease-associated metabolites were determined using a multivariate model comparing 
predicted relative compound levels in health versus Crohn’s disease subjects. Specifically, 
we performed a generalized linear mixed model (glmmPQL, implemented in R), correcting 
for age and medications (antibiotics, immunosuppressants and anti-inflammatory agents). 
Disease-associated metabolites from this analysis were ranked by multi-testing corrected q 
value. From this raw list, the top molecules for which commercial sourcing could be 
identified were tabulated (Supplementary Table 1), and procured for testing.
For prediction of ascorbate-producing microbiota, we used the reverse of this bioinformatics 
pipeline, with the following modifications. Microbial metabolic pathways and enzymes 
involved in ascorbate biosynthesis were defined using KEGG and literature reports. For 
those enzymes annotated in KEGG or MetaCyc databases, we performed a prediction of 
microbiota genomically bearing them using PICRUSt-precalculated gene content. We 
filtered these results for human fecal-associated OTUs, generating lists of OTUs bearing 
various numbers of ascorbate pathway genes. Finally, we filtered for OTUs validated for 
significant differential association in Crohn’s disease versus healthy subjects.
The computational resources for all analytic steps are available at https://bitbucket.org/
biobakery/biobakery/wiki/Home.
Metabolite preparation
All chemical were of cell culture or higher grade, and purchased from Sigma Aldrich. The 
majority of chemicals were dissolved in aqueous solution; water-insoluble metabolites were 
dissolved in DMSO.
Luminex multiplex cytokine production
We measured cytokines from CD4+ T cell culture supernatants using Luminex. The 
following 11 cytokines were included in the Luminex panels and acquired on a Luminex® 
FLEXMAP 3D: Th17 cytokines, IL-17A, IL-17F, and IL-22; Th1 cytokines, TNFα and 
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IFNγ; and Th2 cytokines, IL-5 and IL-13; Treg cytokine, IL-10; other related cytokines, 
IL-9, IL-21, and MIP-3a. We normalized the Luminex readouts for the cell count values.
Detecting ascorbate in bacterial culture
Pseudomonas aeruginosa included two strains, PA-01 and PA-14, obtained from the ATCC. 
Burkholderia cepacia included three clinical isolates (2-1, 3-1, 3-2; source strains ZK2853-
ZK2862) from two cystic fibrosis patients69, a gift from the collection of Robert Kolter 
(Harvard Medical School). Bacteria were cultured in 1 mL Luria-Bretani broth at 35 ± 2°C 
under aerobic condition, and the bacterial cell numbers were monitored by McFarland 
standard 70. After pelleting bacterial cells (5,000 rpm, 10 min), we filtered the supernatants 
using centrifugal filters per manufacturer instructions (Corning® Costar® Spin-X® 
centrifuge tube filters, 0.22μm). We measured ascorbate levels in supernatant filtrates by an 
enzyme-based assay (Abcam, ab65656).
Statistical analysis
To estimate contributors of experimental variability and control for potential technical 
effects, we performed principal variance component analysis (PVCA). The technical factors 
assessed included metabolite, experimental run, donor, and technical replicates in different 
plates. We used PCA to reduce data dimensionality data from the 11 cytokines, and to 
maintain majority of the variability in the data. We used VCA to fit a mixed effect model 
using subject-specific factors as random effects to estimate and partition the total variability. 
Supplementary Figure 3 shows one example. We ran PVCA for every experiment to ensure 
the stability of technical variation.
We used multivariate analysis of variance (MANOVA) to identify putative bioactive 
metabolites. In each condition treated with a specific metabolite concentration, we compared 
the levels of the 11 cytokines to those found in the vehicle control condition. We defined a 
metabolite as bioactive if p-values < 0.05; we confirmed bioactivity in a different healthy 
donor to confirm metabolite bioactivity.
To further validate biological effects and define specific cytokine responses to bioactive 
metabolites, we employed two-way analysis of variance (ANOVA) with metabolite and 
donor factors using the incorporated data from at least two independent experiments. We 
used the Holm-Sidak’s post-test to correct for multiple comparisons. We defined statistical 
significance as adjusted p-values < 0.05.
We generated cytokine heatmaps from Luminex cytokine data by calculating the mean of 
log2 fold change between metabolite-untreated versus metabolite-treated samples (treated/
untreated). We used the heatmap.2 function in gplot package to generate dendrogram and 
colorplot in R version 3.2.4.
We performed statistical analyses with Prism software (GraphPad) or using the R program 
(R version 3.1.1). We used the nonparametric Mann-Whitney test to compare two 
experimental conditions. We defined statistically significant results are indicated (*p < 0.05, 
***p <0.001). We displayed error bars using mean ± SEM calculated from 3 or more 
experimental replicates.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Microbial metabolites screen identifies bioactive metabolites modulating CD4+ T cell 
cytokine profile
(a) Schematic of screening and analytic strategies. Toxic: cell death observed at all tested 
conditions; Potential Bioactive: achieved MANOVA statistical significance cut-off; Putative 
Bioactive: significant effects in first round but not second round of screening, potentially due 
to donor-specific variation; Validated Bioactive: reproducible effects in two individuals 
(achieved statistical significance cutoff by two-way ANOVA test). (b) Aggregate cytokine 
response (negative logarithm of the association p-values calculated from multivariate 
analysis of variance) to candidate metabolites. P<0.0004 represents the significant threshold 
after Holm-Sidak correction for multiple comparisons (Blue dots). (c) Categories of 
response to metabolites (% of all tested metabolites). (d) Summary heatmap of multiplex 
cytokine expression data for the 12 novel validated-bioactive metabolites. We show 
metabolite-treated samples (rows) at the optimal bioactive concentration. Asterisks (*) 
highlight metabolites with dose-dependent effects. CoA: Coenzyme A; HMG-CoA: 3-
hydroxy-3-methyl-glutaryl-coenzyme A. Four metabolites with dose-dependent effects are 
marked with an asterisk (*).
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Figure 2. Representative bioactive metabolites altering CD4+ T cell cytokine secretion
(a) Pan-inhibition of cytokine secretion by GDP mannose. (b) Th17-cytokine inhibition by 
ascorbate. N.A.: condition that causes cell death and excluded. (c, d) Th1-specific cytokine 
augmentation by oleic acid (c) and linoleic acid (d). For each of the two donors (black and 
gray), we calculated mean ± SEM from three technical replicates.
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Figure 3. Ascorbate inhibits T cell cytokines in both polarized and non-polarized conditions
(a,b) CD4+ T cells were cultured with 0 to 1 mM of ascorbate as described in Figure 1. (a) 
Intracellular flow cytometry and (b) Luminex measurement of four biological replicates 
(four colors, mean ± SEM). N.A.: condition that causes cell death and excluded. (c) We 
cultured CD4+ T cells under T cell activation condition with 0 or 0.1 mM of ascorbate. We 
used intracellular flow cytometry to determine the percentages of indicated CD4+ T cells. 
Mean ± SEM calculated from three biological replicates.
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Figure 4. Ascorbate selectively inhibits activated but not resting CD4+ T cells
We cultured CD4+ T cells in 10 ng/ml of IL-7 (resting) or activated with 1ug/ml anti-CD3 
and anti-CD28 antibody (activated) for 48 hours. We assessed T cell activation (CD154+) by 
flow cytometry. (a) Representative plot (b) Summary of the three independent experiments. 
(c) We measured cell death by Annexin V flow cytometry from three independent 
experiments.
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Figure 5. Seahorse platform measurements of OCR and ECAR
(a and b) We cultured CD4+ T cells in 10 ng/ml of IL-7 (resting) or activated with 1ug/ml 
anti-CD3 and anti-CD28 antibody (activated) for 48 hours, with or without 100 μM 
ascorbate treatment. (c and d) Scramble and GLUT1-specific clone of siRNA was 
transfected via Nucleofector™ kit (Lonza). After transfection, cells were rested in 10 ng/ml 
of IL-7 (resting) or activated with 1 ug/ml anti-CD3 and anti-CD28 antibody (activated) for 
48 hours, under the conditions with or without 100 μM ascorbate treatment. (a–d) Each 
seahorse experiment has been performed on three biological donors of cells and one of 
representative plot was shown. Mean ± SEM calculated from 3 technical replicates.
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Figure 6. Gut microbes producing ascorbate
(a) Enzymes involved in the sorbitol pathway or (b) in the 2,5-diketo-D-gluconic acid 
pathway of ascorbate biosynthesis. OTUs: operational taxonomic unit. Left: Numbers of 
OTUs bearing metagenes for the indicated number of pathway enzymes. Right: Bar plots of 
the numbers of OTUs expressing indicated enzymes in bacterial genera. (c) We cultured 
bacteria for 24 hours and then collected supernatants to measure ascorbate levels. Since all 
cultures had reached equivalent McFarland readings at 24 hours, the ascorbate levels 
represent production from comparable cell numbers.
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Table 1
Validated bioactive metabolites.
Metabolite Name HMDB_ID Chemical Category (HMDB)
(S)-3-Hydroxy-3-methylglutaryl-CoA HMDB01375 Fatty Acyls
Hexanoyl-CoA HMDB02845 Fatty Acyls
GDP-mannose HMDB01163 Purine nucleotides
Isopentenyl diphosphate HMDB04196 Prenol lipids
CoA HMDB01423 Purine nucleotides
L-Glutamate HMDB00148 Amino acids, peptides, and analogues
L-Ascorbate HMDB00044 Furanones
L-Homocysteine HMDB00742 Carboxylic acids and derivatives
(R)-Mevalonate HMDB59629 Fatty acids and conjugates
Glutaryl-CoA HMDB01339 Fatty Acyls
Pyridoxine phosphate HMDB01319 Pyridines and derivatives
Oleic acid HMDB00207 Fatty Acid
Arachidonic acid HMDB01043 Fatty Acid
Linoleic acid HMDB00673 Fatty Acid
Butyric acid HMDB00039 Fatty Acid
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